STOCK TITAN

Azenta Inc - AZTA STOCK NEWS

Welcome to our dedicated page for Azenta news (Ticker: AZTA), a resource for investors and traders seeking the latest updates and insights on Azenta stock.

Overview of Azenta Inc

Azenta Inc (Nasdaq: AZTA) is a highly specialized provider of life sciences solutions that play a critical role in accelerating breakthroughs in drug development, clinical research, and advanced cell therapies. Leveraging industry-specific expertise in cold-chain sample management and multiomics services, Azenta supports its global clientele of top pharmaceutical, biotech, academic, and healthcare institutions. With robust worldwide operations across North America, Europe, and Asia, the company has strategically positioned itself to deliver precision, reliability, and operational efficiency in high-stakes research environments.

Business Segments and Core Operations

The company operates through two primary segments: Life Sciences Products and Life Sciences Services. Its Life Sciences Products segment provides an array of proprietary and industry-leading lab consumables, automated storage systems, and cold-chain logistics solutions. The Life Sciences Services segment focuses on an integrated suite of genomic, proteomic, and multiomics analytics that are essential for enabling transformative scientific research and clinical trials. These services facilitate rapid sample processing, accurate data generation, and streamlined workflows, ensuring high-quality results that underpin critical decisions in drug discovery and patient care.

Innovative Solutions and Technological Excellence

Azenta’s commitment to innovation is evident in its continuous enhancement of technologies that maintain sample integrity and deliver high-accuracy genomics data. The company excels in cold-chain sample management through its automated systems that ensure temperature-controlled preservation of biological specimens. In multiomics analyses, state-of-the-art next-generation sequencing (NGS) and long-read whole genome sequencing technologies are employed to offer detailed insights into genomic complexities. This blend of cutting-edge automation and high-fidelity sequencing distinguishes Azenta in a competitive market, enabling researchers to overcome traditional limitations and achieve breakthroughs faster.

Global Reach and Operational Excellence

Headquartered in the United States, Azenta has established an influential global presence with operations spanning major regions. Its strategic hubs in North America, Europe, and Asia facilitate efficient service delivery and logistical coordination across multiple time zones. This global footprint not only enhances the company’s ability to support international research initiatives but also underscores its operational resilience and commitment to quality service delivery.

Commitment to Quality and Impactful Research

  • Reliable Cold-Chain Management: Ensures the integrity and stability of sensitive biological samples throughout their lifecycle.
  • Comprehensive Multiomics Services: Provides advanced genomic, proteomic, and bioinformatics solutions tailored to facilitate expansive research projects.
  • Innovative Automation Systems: Streamlines laboratory processes and enhances throughput while maintaining precision and compliance with rigorous industry standards.

Position in the Industry

Within the competitive landscape of life sciences, Azenta stands out for its dual focus on products and services that address the nuanced needs of modern biomedical research. The company’s integration of reliable sample management with advanced genomics and multiomics analytics offers a distinct value proposition by enabling research institutions to achieve faster and more accurate results. Its solutions are instrumental in overcoming challenges such as sample degradation, logistical inefficiencies, and data variability, which are common obstacles in traditional research settings.

Expertise and Industry Recognition

Azenta’s expertise is built on deep scientific knowledge and extensive operational experience. With a team of dedicated professionals and scientists, the company continuously advances its methodologies to meet the evolving demands of precision medicine and clinical research. This commitment to excellence is recognized within the industry through collaborations with academic institutions, participation in groundbreaking research studies, and a robust portfolio of innovations that support large-scale projects globally.

In-depth Look at Key Service Offerings

Cold-Chain Sample Management: Azenta provides an end-to-end solution for the preservation, transportation, and storage of biological samples. Through its advanced automated systems, the risk of sample degradation is minimized, thereby supporting high-quality downstream analyses.

Multiomics and Genomic Services: With a comprehensive suite of services, including next-generation sequencing and proteomics profiling, the company enables researchers to explore complex biological pathways, identify biomarkers, and drive therapeutic advancements. These services are underpinned by rigorous quality controls and innovative data analytics that significantly enhance the reliability and reproducibility of research findings.

Supporting Research Initiatives and Client Collaborations

Azenta is a trusted partner in numerous research initiatives, working closely with renowned researchers and institutions to support pivotal studies in areas such as inflammatory bowel disease, precision medicine, and clinical genomics. Through its specialized service offerings, Azenta not only provides the necessary technological infrastructure but also the expertise required to optimize research outcomes. These collaborations underscore the company’s role as a facilitator of significant scientific progress.

Conclusion

In summary, Azenta Inc represents a comprehensive and innovative force within the life sciences sector. By seamlessly integrating cold-chain sample management with forward-thinking genomic and multiomics services, the company provides unparalleled support to leading research institutions across the globe. Its operational excellence, technological expertise, and commitment to quality research render it an invaluable resource for those seeking to drive impactful scientific breakthroughs and improve therapeutic outcomes.

Rhea-AI Summary

Azenta (Nasdaq: AZTA) has released its 2024 Environmental, Social, & Governance (ESG) Report, outlining achievements across three main pillars: Environmental Protection, Social Impact, and Responsible Operations.

Key 2024 milestones include:

  • ~20% reduction in Scope 1 & 2 Greenhouse Gas emissions compared to 2022
  • Over 60% electricity sourced from renewable sources
  • Launch of BioArc™ Ultra for eco-friendly sample storage
  • Introduction of LGBTQIA+ Employee Resource Group (Azenta PRISM)
  • Implementation of Azenta THRIVE platform with LinkedIn Learning® integration
  • 100% of global buyer team trained on sustainable sourcing
  • EcoVadis® partnership expansion to evaluate ESG performance of over 50% of Tier 1 suppliers by spend
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.83%
Tags
none
-
Rhea-AI Summary

Azenta (Nasdaq: AZTA) has announced its participation in the upcoming Virtual KeyBanc Capital Markets Healthcare Forum. The company's Executive Vice President and Chief Financial Officer, Lawrence Y. Lin, will deliver a presentation at the event on Wednesday, March 19, 2025, at 10:30 am ET.

Investors and interested parties can access the live webcast through the Azenta investor relations website at https://investors.azenta.com/events. A replay option will be made available after the presentation concludes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.62%
Tags
conferences
-
Rhea-AI Summary

Azenta (NASDAQ: AZTA) reported Q1 FY2025 results with revenue from continuing operations at $148 million, up 4% year-over-year. The company's performance was marked by growth in both major segments: Sample Management Solutions revenue reached $81 million (+3% YoY) and Multiomics revenue hit $66 million (+6% YoY).

The company reported a diluted EPS loss of ($0.21) from continuing operations and total diluted EPS of ($0.29). Adjusted EBITDA was $13 million with a margin of 9.0%, showing a 400 basis point improvement year-over-year. The quarter ended with $530 million in cash, cash equivalents, and marketable securities, generating free cash flow of $22 million.

For FY2025, Azenta maintains its guidance of 3-5% organic revenue growth and expects adjusted EBITDA margin expansion of approximately 300 basis points compared to FY2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.44%
Tags
Rhea-AI Summary

Azenta (NASDAQ: AZTA) announced the election of Dipal Doshi to its Board of Directors at its Annual Meeting of Stockholders. Doshi, who currently serves as the Chief Executive Officer of Entrada Therapeutics (NASDAQ: TRDA), brings extensive experience in the biotechnology and pharmaceutical industries.

John Marotta, President and CEO of Azenta, highlighted Doshi's exceptional leadership qualities and valuable experience in strategy, operational and commercial growth, along with his perspective as a current public company CEO. Doshi expressed enthusiasm about joining Azenta during a important period in its development, emphasizing the company's strong market leadership position and commitment to growth and innovation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
management
-
Rhea-AI Summary

Azenta (Nasdaq: AZTA) has announced it will release its fiscal first quarter 2025 financial results on Wednesday, February 5, 2025, before market opening. The earnings report will cover the period ended December 31, 2024.

The company will host a conference call and live webcast to discuss the results on the same day at 8:30 a.m. Eastern Time. The webcast will be accessible through Azenta's investor relations website, with a replay available starting February 6, 2025, at 8:30 a.m. ET.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
conferences earnings
-
Rhea-AI Summary

Azenta (Nasdaq: AZTA) has been selected by UK Biocentre to provide its BioArc Ultra automated storage system for expanding large-scale sample storage capabilities. This addition complements seven existing BioArc Flex systems at their facility. The new system will be installed at UK Biocentre's 70,000 square-foot facility in Milton Keynes, England.

The BioArc Ultra will increase the facility's storage capacity by 16 million samples, adding to its current 35 million sample capacity. The system features high-density, fully automated -80°C storage with picking capability of up to 9 million picks per year. The solution includes FluidX 2D-coded screw-cap tubes for enhanced inventory management.

Key benefits include reduced footprint, lower labor requirements, and decreased electricity costs. The system employs an eco-friendly refrigeration system with zero Ozone Depletion Potential and zero Global Warming Potential. UK Biocentre will use this technology to support the Our Future Health study, which aims to develop new ways to prevent, detect, and treat diseases across up to 5 million people in the UK.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
none
Rhea-AI Summary

Azenta (Nasdaq: AZTA) has announced its participation in the Stephens Annual Investment Conference on Wednesday, November 20, 2024. The company's management will deliver a presentation starting at 1:00 pm CT. Investors and interested parties can access the live webcast through Azenta's investor relations website. A replay option will be made available after the event concludes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.24%
Tags
conferences
-
Rhea-AI Summary

Azenta reported its Q4 and FY 2024 results, highlighting a 4% revenue growth in Sample Management Solutions and Multiomics. The company anticipates a 3%-5% organic revenue growth for FY 2025 and a 300 basis points EBITDA margin expansion. For Q4, revenue was $170 million, down 1% YoY, with a 2% organic decline. Sample Management Solutions and Multiomics grew by 5% and 8% organically, respectively, while B Medical Systems saw a 35% decline. FY 2024 revenue was $656 million, down 1% YoY, driven by a 27% decline in B Medical Systems revenue. The company reported an operating loss of $201 million for FY 2024, with a non-GAAP diluted EPS of $0.41. Azenta plans to sell B Medical Systems to focus on core businesses and appointed Lawrence Y. Lin as the new CFO. They ended FY 2024 with $522 million in cash and equivalents and repurchased 4.9 million shares worth $249 million in Q4.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.22%
Tags
management earnings
-
Rhea-AI Summary

Azenta (Nasdaq: AZTA) has scheduled its fiscal fourth quarter and full year 2024 earnings announcement for Tuesday, November 12, 2024, after market close. The company will host a conference call and live webcast at 4:30 p.m. Eastern Time on the same day to discuss the financial results for the period ended September 30, 2024. A replay of the webcast will be available starting at 8:30 a.m. ET on November 13, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.83%
Tags
conferences earnings
Rhea-AI Summary

Azenta (NASDAQ: AZTA) has appointed three new independent directors to its Board: William Cornog (former head of KKR Capstone), Quentin Koffey (Founder of Politan Capital Management, owning 9.4% of Azenta), and Alan Malus (former Executive VP of Thermo Fisher). The company established a new Value Creation Committee to focus on long-term value creation, growth initiatives, and capital deployment. The committee will be chaired by William Cornog and includes the new directors along with CEO John Marotta and current director Martin Madaus. Azenta has also reaffirmed its full-year 2024 financial guidance previously announced on August 6th, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.95%
Tags
none

FAQ

What is the current stock price of Azenta (AZTA)?

The current stock price of Azenta (AZTA) is $29.12 as of April 4, 2025.

What is the market cap of Azenta (AZTA)?

The market cap of Azenta (AZTA) is approximately 1.3B.

What primary services does Azenta Inc offer?

Azenta provides a full suite of life sciences solutions, including cold-chain sample management and comprehensive genomic and multiomics services that support drug development, clinical research, and advanced cell therapies.

In which geographic regions does Azenta operate?

Azenta operates globally with key operations in North America, Europe, and Asia, ensuring a robust international presence.

How does Azenta support clinical research initiatives?

The company supports clinical research through its reliable sample management systems and advanced genomic services, enabling accurate data generation and streamlined workflows for high-impact studies.

What distinguishes Azenta’s technological solutions?

Azenta’s solutions are distinguished by their integration of automated cold-chain management and state-of-the-art sequencing technologies that ensure sample integrity and high-fidelity data, meeting rigorous industry standards.

How does Azenta manage to maintain high-quality research outputs?

By combining innovative automation with comprehensive quality controls, Azenta minimizes sample variability and degradation, thereby enhancing the reliability and reproducibility of research findings.

What is the significance of Azenta’s Life Sciences Services segment?

The Life Sciences Services segment is key to Azenta’s business model, offering comprehensive genomic and multiomics analytics that enable researchers to accelerate therapeutic discoveries and clinical breakthroughs.

How does Azenta contribute to accelerating drug development?

Through its advanced sample management and genomics services, Azenta enables faster, more accurate analysis of biological samples, which is essential for uncovering critical insights in drug development.

Who are the primary clients of Azenta Inc?

Azenta serves top pharmaceutical companies, biotech firms, academic institutions, and healthcare providers, all of whom rely on its innovative solutions to support their research and clinical programs.
Azenta Inc

Nasdaq:AZTA

AZTA Rankings

AZTA Stock Data

1.31B
44.91M
1.66%
116.04%
9.26%
Medical Instruments & Supplies
Special Industry Machinery, Nec
Link
United States
BURLINGTON